Myriad Genetics, Inc. (MYGN) Bank of America Merrill Lynch Health Care Conference Call May 16, 2012 7:20 pm ET Executives Peter D. Meldrum – President, Chief Executive Officer and Director Analysts Derik de Bruin – Bank of America Merrill Lynch PresentationDerik de Bruin – Bank of America Merrill Lynch
Merrill Lynch 2012 Health Care Conference. I’m Derik De Bruin, the Life Sciences Tools & Diagnostics analyst. It’s my pleasure to introduce our company, Myriad Genetics. Today from Myriad we have Pete Meldrum, Chief Executive Officer and Jim Evans, Chief Financial Officer. There will be a short presentation and a follow-up by Q&A. And with that, I’ll turn over to Pete. Pete? Peter D. Meldrum Thank you, Derik, and welcome to Myriad Genetics presentation. I will point out that I may be making some forward-looking statements, so please consult our Securities Filings, in particular the 10-Q and 10-K and 8-K reports. Myriad Genetics is a leading molecular diagnostic company focused on the development and discovery of transformative products that benefit patients and stays alive. These tests are involved in affecting an individual’s risk of developing cancer and other major diseases later in life, products that guide treatment decisions so that the patient can get the right drug at the right time, and with the right dose and assessing risk of progression, so that we don’t over treat patients, but can aggressively treat those patients who have a more aggressive form of disease. Myriad has a very broad portfolio of products, nine innovative tests that the company has launched and are commercially selling. And that’s backed up by a very strong product pipeline. The thirteen industry-leading under tests under development across multiple disease indication.